Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib
Authors:
- Enrico DerenziniEDEnrico Derenzini
- Anas YounesAYAnas Younes
- 26 February 2013
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 22 (6) , 775-785
Abstract
(2013). Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. Expert Opinion on Investigational Drugs: Vol. 22, No. 6, pp. 775-785. doi: 10.1517/13543784.2013.775244Keywords
This publication has 89 references indexed in Scilit:
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated DiseaseImmunity, 2012
- The Transcription Factor STAT3 Is Required for T Helper 2 Cell DevelopmentImmunity, 2011
- Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and HomeostasisImmunity, 2010
- Priming for T helper type 2 differentiation by interleukin 2–mediated induction of interleukin 4 receptor α-chain expressionNature Immunology, 2008
- Cytokine Signaling Modules in Inflammatory ResponsesImmunity, 2008
- Nonredundant roles for Stat5a/b in directly regulating Foxp3Blood, 2007
- The role of Janus kinases in haemopoiesis and haematological malignancyBritish Journal of Haematology, 2006
- Selective regulatory function of Socs3 in the formation of IL-17-secreting T cellsProceedings of the National Academy of Sciences, 2006
- CYTOKINE RECEPTOR SIGNAL TRANSDUCTION AND THE CONTROL OF HEMATOPOIETIC CELL DEVELOPMENTAnnual Review of Cell and Developmental Biology, 1996
- Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling ProteinsScience, 1994